Tribune News Service
New Delhi, September 15
The ICMR said on Tuesday early evidence from one of its randomised controlled trials on the efficacy of convalescent plasma has shown that the therapy did not reduce mortality nor did it prevent progression from moderate to severe disease.
ICMR chief Balram Bhargava said the study conducted on 464 patients across 39 hospitals was still under peer review and full publication of the results was awaited.
“Once we get the final publication we will take a decision on whether to continue advising use of plasma therapy as an off label therapy for COVID management in India,” Bhargava said indicating possibilities of review of the previous guidance by ICMR and consequent anxiety among a host of COVID patients to secure convalescent plasma.
Several states have gone to the extent of setting up plasma banks with the efficacy of the therapy still unproven.
Sixth such meeting since June 6
PM Modi calls passage of farm bills ‘watershed moment’ for a...
12 Opp parties give notice of no-confidence against RS deput...
Speaker adjourned the House due to unavailability of seating...
Some activists tried to set a tractor on fire after the marc...